SNN - Smith & Nephew reports Q1 results

Smith & Nephew press release (NYSE:SNN): Q1 Revenue of $1.31B (+3.3% Y/Y) beats by $40M. Sports Medicine & ENT revenue up 8.6% underlying; Advanced Wound Management revenue up 8.0% underlying; Orthopaedics revenue up 2.6% underlying. Full year 2022 guidance remains unchanged. For the year, the company is targeting underlying revenue growth of 4.0% to 5.0%. On a reported basis the guidance equates to a range of around 1.3% to 2.3%, with a foreign exchange headwind of 270bps based on exchange rates prevailing on 22 April 2022. The Consensus Revenue Estimate for 2022 is $5.37B. CEO update: "Our Q1 performance puts us on track to deliver our guidance for this year. 2022 marks an important stepping-stone in our Strategy for Growth and towards achieving our medium-term financial performance commitments. I am excited by the prospect of driving delivery of the Strategy and bringing out the best in Smith+Nephew to realize the full potential of the

For further details see:

Smith & Nephew reports Q1 results